霍奇金淋巴瘤治疗研究进展

Progress of treatment of Hodgkin lymphoma

大多数霍奇金淋巴瘤（HL）可以治愈，目前的一线治疗通常采用ABVD方案（多柔比星、博来霉素、长春碱和达卡巴嗪）化疗或联合放疗。但是复发难治HL治疗依旧是一个巨大的挑战。大剂量化疗序贯自体造血干细胞移植对该类患者最为受益，同时维布妥昔单抗（BV）联合程序性死亡受体1单抗nivolumab、BV联合ICE（异环磷酰胺、卡铂、依托泊苷）、帕比司他（panobinotast）联合ICE等方案以及许多新药正在临床试验和研发中。第58届美国血液学会（ASH）年会对HL的最新治疗进展进行了深入报道。

Hodgkin lymphoma （HL） is a highly curable malignancy for most patients. Frontline treatment is generally ABVD alone or combination with other chemotherapy regimens or radiation. However, the treatment of relapsed refractory HL （RR HL） remains a major challenge for clinicians. High dose chemotherapy followed by autologous stem cell transplantation is the preferred treatment for chemoresistant patients. In addition, the combination of brentuximab vedotin （BV） with programmed cell death receptor 1 monoclonal antibody nivolumab, BV combined with ICE （ifosfamide, earboplatin, etoposide）, panobinotast in combination with ICE and many other new drugs are in clinical trials and research. The latest progress in treatment of HL is reported in depth in the 58th American Society of Hematology Annual Meeting.